title: [Development and study of structure-activity relationship of drugs against Mycobacterium tuberculosis].
abstract: Tuberculosis is considered to be one of the major health problem not only in the less developed countries but in the economically developed countries as well. Roughly one third of the world's population are infected with Mycobacterium tuberculosis and a significant part of them are carriers of latent tuberculosis. From ten percent of these latent infections are developing the active TB disease and fifty percent of them die from the illness without appropriate treatment. The drug-resistant Mycobacterium tuberculosis (MDR-TB, XDR-TB) and TB-HIV co-infection attracted attention to the most serious infectious disease. Inhibition of alternative signaling pathways were an important part of the research strategies for cancer and inflammatory diseases in recent years. In case of Mycobacterium tuberculosis such pathways were also identified, for example, three serine-threonine kinases (PknA, PknB, PknG) which are necessary and essential for bacterial growth. In this paper we summarize our best anti-TB active compounds, their biological effects and structure-activity relationships using in silico modeling, biochemical measurements and tests on active bacteria.
authors.affiliation: Racionális Hatóanyagtervezo Laboratóriumok, Semmelweis Egyetem.
authors.forename: Ferenc
authors.initials: F
authors.lastname: Baska
authors.affiliation: Vichem Chemie Kutató Kft.
authors.forename: Edina Rita
authors.initials: ER
authors.lastname: Székely
authors.affiliation: Vichem Chemie Kutató Kft.
authors.forename: Csaba
authors.initials: C
authors.lastname: Szántai-Kis
authors.affiliation: Vichem Chemie Kutató Kft.
authors.forename: Péter
authors.initials: P
authors.lastname: Bánhegyi
authors.affiliation: Vichem Chemie Kutató Kft.
authors.forename: Bálint
authors.initials: B
authors.lastname: Hegymegi-Barakonyi
authors.affiliation: Vichem Chemie Kutató Kft.
authors.forename: Gábor
authors.initials: G
authors.lastname: Németh
authors.affiliation: Vichem Chemie Kutató Kft.
authors.forename: Nóra
authors.initials: N
authors.lastname: Breza
authors.affiliation: Orvosi Vegytani, Molekuláris Biológiai és Patobiokéimiai Intézet, Semmelweis Egyetem.
authors.forename: Lilian
authors.initials: L
authors.lastname: Zsákai
authors.affiliation: Vichem Chemie Kutató Kft.
authors.forename: Zoltán
authors.initials: Z
authors.lastname: Greff
authors.affiliation: Vichem Chemie Kutató Kft.
authors.forename: János
authors.initials: J
authors.lastname: Pató
authors.affiliation: Racionális Hatóanyagtervezo Laboratóriumok, Semmelweis Egyetem.
authors.forename: György
authors.initials: G
authors.lastname: Kéri
authors.affiliation: Racionális Hatóanyagtervezo Laboratóriumok, Semmelweis Egyetem.
authors.forename: Lászlo
authors.initials: L
authors.lastname: Orfi
mesh_terms: D019732:Amide Synthases / Q000037:antagonists & inhibitors*; D000577:Amides / Q000737:chemistry / Q000494:pharmacology; D000995:Antitubercular Agents / Q000737:chemistry* / Q000494:pharmacology*; D060085:Coinfection / Q000453:epidemiology; D003198:Computer Simulation; D015658:HIV Infections / Q000453:epidemiology; D006801:Humans; D020128:Inhibitory Concentration 50; D020935:MAP Kinase Signaling System / Q000187:drug effects; D008956:Models, Chemical; D009169:Mycobacterium tuberculosis / Q000187:drug effects*; D017346:Protein Serine-Threonine Kinases / Q000378:metabolism; D013329:Structure-Activity Relationship; D013876:Thiophenes / Q000737:chemistry / Q000494:pharmacology; D014376:Tuberculosis / Q000188:drug therapy* / Q000453:epidemiology; D018088:Tuberculosis, Multidrug-Resistant / Q000188:drug therapy
chemical_list: C487783:AX 20017; D000577:Amides; D000995:Antitubercular Agents; D013876:Thiophenes; D017346:Protein Serine-Threonine Kinases; D019732:Amide Synthases; C038479:NAD+ synthase